Abstract:Parkinson's disease (PD) is characterized pathologically by the selective loss of substantia nigra (SN) dopaminergic (DAergic) neurons. Recent evidence has suggested a role of LRRK2, linked to the most frequent familial PD, in regulating synaptic vesicle (SV) trafficking. However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear. Here we show that the most common PD mutationLRRK2 G2019Simpairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity. A similar endocytic defect, however, was not observed in LRRK2 mutant neurons from the neocortex (hereafter, cortical neurons) or the hippocampus, suggesting a brain region-specific vulnerability to the G2019S mutation. Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion ofSYNJ1(PARK20), a gene that is associated with recessive Parkinsonism. CombiningSYNJ1+/−andLRRK2 G2019Sdoes not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice. Interestingly, we show that LRRK2 directly phosphorylates synaptojanin1in vitro, resulting in the disruption of endophilin-synaptojanin1 interaction required for SV endocytosis. Our work suggests a merge ofLRRK2andSYNJ1pathogenic pathways in deregulating SV trafficking in MB neurons as an underlying molecular mechanism of early PD pathogenesis.SIGNIFICANCE STATEMENTUnderstanding midbrain dopaminergic (DAergic) neuron-selective vulnerability in PD is essential for the development of targeted therapeutics. We report, for the first time, a nerve terminal impairment in SV trafficking selectively in MB neurons but not cortical neurons caused by two PARK genes:LRRK2(PARK8) andSYNJ1(PARK20). We demonstrate that the enhanced kinase activity resulting from the most frequentG2019Smutation inLRRK2is the key to this impairment. We provide evidence suggesting thatLRRK2 G2019SandSYNJ1loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.

How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease

Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson's Disease?

Leucine-rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration

The Role of the LRRK2 Gene in Parkinsonism

LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

“LRRK2: Autophagy and Lysosomal Activity”

Kinase Activity of Mutant LRRK2 Mediates Neuronal Toxicity

Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons

LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons

Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease

Advance of the Study on LRRK2 Gene in Parkinson's Disease

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease

Leucine-Rich Repeat Kinases